Novo Nordisk Says Semaglutide Cut Obesity Rates in Young Children in Trial

3-line summary

• Novo Nordisk said semaglutide cut obesity rates in young children in a trial, according to an Investing.com report.

This summary is our own processing of the source article; see the source link below for full context.